Patrick Tsang interviews Anthony Cataldo, the CEO of GT Biopharma, a clinical-stage immuno-oncology company developing innovative therapies based on proprietary NK cell engager (TriKE®) technology. In this interview in Monaco, Anthony shares his career path, including Iovance Biotherapeutics, leading to his work in immuno-oncology with GT Biopharma, and lessons learned becoming CEO. He speaks about the importance of data and clinical trials for GT Biopharma to target cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and multiple solid tumors. In addition, he has extensive experience in the biotechnology sector.

More about Anthony Cataldo:

https://www.gtbiopharma.com